PPD teams up with Cancer Treatment Centers of America to boost oncology trials

PPD
Using PPD's so-called Optimal Just-in-Time service, it paired up with Cancer Treatment Centers of America on its network of hospitals. (PPD)

PPD is working with Cancer Treatment Centers of America (CTCA) to speed up enrollment into cancer studies.

Using the CRO’s so-called Optimal Just-in-Time service (part of PPD’s Accelerated Enrollment Solutions business unit), it paired up with CTCA on its network of hospitals.

Working together, the two groups have “significantly shortened site activation time from as long as eight months to as little as two weeks … Metrics generated by CTCA demonstrate results that surpass traditional sites on the same trials when evaluating data currency, query rates, deviations and retention,” PPD said in a statement.

Submissions Open

Fierce Innovation Awards: Life Sciences Edition 2020

Submit your entry to demonstrate innovative technologies and services that have the potential to make the greatest impact for biotech and pharma companies.

PPD’s approach here is based on establishing a community of sites with prenegotiated contracts and terms, which provides “immediate engagement by sites to search for patients.” It explains that patients are identified first, triggering the activation of sites and enabling patients to be enrolled within two weeks. As a result of the efficiencies of this process, there are zero non-enrolling sites.

“Our collaboration with CTCA demonstrates how we are changing the paradigm of cancer care,” says Krystyna Kowalczyk, chief operating officer for Optimal service offerings.

“Together, we are creating meaningful opportunities for cancer patients to participate in clinical trials and access innovative therapies close to home, allowing them to receive care within the context of their support networks in their own communities. Some 30% of the patients we enroll with CTCA are from under-represented populations, which reflects our goal of expanding clinical trial opportunities more broadly. Our goal is to enroll more patients from fewer sites in less time to support important oncology trials. Thanks to our JIT methodology, a two-week turnaround for first-patient-in is now possible.”

Suggested Articles

The National Institute of Allergy and Infectious Diseases is launching a new clinical trials network for COVID-19.

In a mix-up of trial-based solutions, CRO Parexel is using its recent partnership with Datavant to run a pact with life science data firm TriNetX.

With stints at Genzyme, Bayer and, most recently, TranScrip Partners, Gilbert Wagener, M.D., Ph.D., is now signing up to U.K. biotech Rexgenero.